176 related articles for article (PubMed ID: 34348622)
1. Current Scenario of Acridine Hybrids with Anticancer Potential.
Zhang Q; Yu X
Curr Top Med Chem; 2021; 21(19):1773-1786. PubMed ID: 34348622
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
Zhang W; Zhang B; Zhang W; Yang T; Wang N; Gao C; Tan C; Liu H; Jiang Y
Eur J Med Chem; 2016 Jun; 116():59-70. PubMed ID: 27060757
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of Acridine/Acridone Analogs as Potential Anticancer Agents.
Gensicka-Kowalewska M; Cichorek M; Ronowska A; Deptuła M; Klejbor I; Dzierzbicka K
Med Chem; 2019; 15(7):729-737. PubMed ID: 30324889
[TBL] [Abstract][Full Text] [Related]
5. Study on one-pot four-component synthesis of 9-aryl-hexahydro-acridine-1,8-diones using SiO2-I as a new heterogeneous catalyst and their anticancer activity.
Ramesh KB; Pasha MA
Bioorg Med Chem Lett; 2014 Aug; 24(16):3907-13. PubMed ID: 25042338
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents.
Gao C; Li B; Zhang B; Sun Q; Li L; Li X; Chen C; Tan C; Liu H; Jiang Y
Bioorg Med Chem; 2015 Apr; 23(8):1800-7. PubMed ID: 25778766
[TBL] [Abstract][Full Text] [Related]
8. Novel synthetic acridine derivatives as potent DNA-binding and apoptosis-inducing antitumor agents.
Lang X; Li L; Chen Y; Sun Q; Wu Q; Liu F; Tan C; Liu H; Gao C; Jiang Y
Bioorg Med Chem; 2013 Jul; 21(14):4170-7. PubMed ID: 23735826
[TBL] [Abstract][Full Text] [Related]
9. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
Antonini I; Polucci P; Magnano A; Sparapani S; Martelli S
J Med Chem; 2004 Oct; 47(21):5244-50. PubMed ID: 15456268
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
[TBL] [Abstract][Full Text] [Related]
13. A Novel Series of N-aryltriazole and N-acridinyltriazole Hybrids as Potential Anticancer Agents.
Rono CK; Darkwa J; Meyer D; Makhubela BCE
Curr Org Synth; 2019; 16(6):900-912. PubMed ID: 31984911
[TBL] [Abstract][Full Text] [Related]
14. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
15. Identification of amino acid appended acridines as potential leads to anti-cancer drugs.
Singh P; Kumar A; Sharma A; Kaur G
Bioorg Med Chem Lett; 2015 Sep; 25(18):3854-8. PubMed ID: 26238321
[TBL] [Abstract][Full Text] [Related]
16. Interest of acridine derivatives in the anticancer chemotherapy.
Demeunynck M; Charmantray F; Martelli A
Curr Pharm Des; 2001 Nov; 7(17):1703-24. PubMed ID: 11562307
[TBL] [Abstract][Full Text] [Related]
17. Acridine and acridone derivatives, anticancer properties and synthetic methods: where are we now?
Belmont P; Bosson J; Godet T; Tiano M
Anticancer Agents Med Chem; 2007 Mar; 7(2):139-69. PubMed ID: 17348825
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
19. Natural and synthetic acridines/acridones as antitumor agents: their biological activities and methods of synthesis.
Cholewiński G; Dzierzbicka K; Kołodziejczyk AM
Pharmacol Rep; 2011; 63(2):305-36. PubMed ID: 21602588
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of modified acridines: the effect of N- and O- substituent in the nitrogenated ring on antitumor activity.
Sánchez I; Reches R; Caignard DH; Renard P; Pujol MD
Eur J Med Chem; 2006 Mar; 41(3):340-52. PubMed ID: 16413635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
